Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (ALLO-WT1) [Etude Phase I/II d'immunotherapie Par proteine recWT1-A10+AS01B apres Greffe allogenique de Cellules Souches]
Phase of Trial: Phase I/II
Latest Information Update: 23 Mar 2015
Price : $35 *
At a glance
- Drugs Acute myeloid leukaemia vaccine (Primary) ; AS01B
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacodynamics
- Acronyms ALLO-WT1
- 19 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jul 2013 New source identified and integrated: European Clinical Trials Database record.
- 10 May 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.